Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds

Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds
A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a Phase 1/2 trial shows. The findings suggest that weekly chemotherapy might be more suitable for these patients than the standard every-three-week dosing, and should be investigated in larger Phase 3 trials. The study, "Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients," was published in the International Journal of Gynecological Cancer. Lynparza, marketed by AstraZeneca and the first PARP inhibitor used to treat ovarian cancer, has come to significantly improve the outcomes of these patients. However, initial attempts to combine Lynparza with standard chemotherapy regimens were disappointing, with most patients experiencing severe toxicity. Chemotherapy with Paraplatin (carboplatin) and Taxol (paclitaxel) is usually given once every three weeks to ovarian cancer patients. But studies suggest that a weekly regimen might be safer, with patients reporting better quality of life scores and fewer adverse events. Researchers conducted a Phase 1/2 trial (NCT01650376) to assess the feasibility of combining Lynparza and weekly chemotherapy in heavily-treated women with ovarian cancer. In the first of this two-part study, researchers tested escalating doses of Lynparza, along with chemotherapy, to determine the safest dose for additional testing. The recommended dose — 150 mg tablets twice daily each week, on first three days of each week —  was then tested in a larger group of patients to determine its efficacy and to continue assessing safety. Patients in both groups
Subscribe or to access all post and page content.